Paul J Van Diest

List of Publications by Year
in descending order

324	11,458	36303	46799
papers	citations	51 h-index	89 g-index

328	328	328	14528
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. Journal of Pathology, 2001, 195, 451-456.	4.5	681
2	An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nature Medicine, 2019, 25, 838-849.	30.7	486
3	Supplemental MRI Screening for Women with Extremely Dense Breast Tissue. New England Journal of Medicine, 2019, 381, 2091-2102.	27.0	388
4	Assessment of algorithms for mitosis detection in breast cancer histopathology images. Medical Image Analysis, 2015, 20, 237-248.	11.6	338
5	Reproducibility of mitosis counting in 2,469 breast cancer specimens: Results from the Multicenter Morphometric Mammary Carcinoma Project. Human Pathology, 1992, 23, 603-607.	2.0	326
6	Prognostic value of proliferation in invasive breast cancer: a review. Journal of Clinical Pathology, 2004, 57, 675-681.	2.0	299
7	Digital pathology: current status and future perspectives. Histopathology, 2012, 61, 1-9.	2.9	285
8	For and against: No consent should be needed for using leftover body material for scientific purposes * For * Against. BMJ: British Medical Journal, 2002, 325, 648-651.	2.3	221
9	Tumor-Specific Uptake of Fluorescent Bevacizumabâ€“IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study. Clinical Cancer Research, 2017, 23, 2730-2741.	7.0	212
10	Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2018, 110, 568-580.	6.3	198
11	Targeting <scp>DDX</scp>3 with a small molecule inhibitor for lung cancer therapy. EMBO Molecular Medicine, 2015, 7, 648-669.	6.9	189
12	Predicting breast tumor proliferation from whole-slide images: The TUPAC16 challenge. Medical Image Analysis, 2019, 54, 111-121.	11.6	182
13	Going fully digital: Perspective of a Dutch academic pathology lab. Journal of Pathology Informatics, 2013, 4, 15.	1.7	135
14	EGFR targeted nanobodyâ€“photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer. Journal of Controlled Release, 2016, 229, 93-105.	9.9	132
15	Pathology of hereditary breast cancer. Cellular Oncology (Dordrecht), 2011, 34, 71-88.	4.4	123
16	Molecular subtyping of male breast cancer by immunohistochemistry. Modern Pathology, 2012, 25, 398-404.	5.5	113
17	Effects of Chemotherapy on Pathologic and Biologic Characteristics of Locally Advanced Breast Cancer. American Journal of Clinical Pathology, 1997, 107, 211-218.	0.7	104
18	No consent should be needed for using leftover body material for scientific purposes. For. BMJ, The, 2002, 325, 648-51.	6.0	101

#	Article	IF	Citations
19	Pathology of silicone leakage from breast implants. Journal of Clinical Pathology, 1998, 51, 493-497.	2.0	97
20	Prospective Multicenter Validation of the Independent Prognostic Value of the Mitotic Activity Index in Lymph Nodeâ€"Negative Breast Cancer Patients Younger Than 55 Years. Journal of Clinical Oncology, 2005, 23, 5993-6001.	1.6	94
21	Creation of a fully digital pathology slide archive by high-volume tissue slide scanning. Human Pathology, 2010, 41, 751-757.	2.0	92
22	A Novel Less-invasive Approach for Axillary Staging After Neoadjuvant Chemotherapy in Patients With Axillary Node-positive Breast Cancer by Combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): A Dutch Prospective Multicenter Validation Study. Clinical Breast Cancer, 2017, 17, 399-402.	2.4	91
23	Are Locoregional Cutaneous Metastases in Melanoma Predictable?. Annals of Surgical Oncology, 1999, 6, 315-321.	1.5	83
24	Reliability of the Sentinel Node Procedure in Melanoma Patients: Analysis of Failures After Long-Term Follow-Up. Annals of Surgical Oncology, 2000, 7, 461-468.	1.5	81
25	Prognostic value of estrogen receptor Î± and progesterone receptor conversion in distant breast cancer metastases. Cancer, 2012, 118, 4929-4935.	4.1	81
26	Ultrasound-guided lumpectomy of nonpalpable breast cancers: A feasibility study looking at the accuracy of obtained margins. , 1999, 72, 72-76.		80
27	Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer. Oncotarget, 2015, 6, 28312-28326.	1.8	79
28	The value of autopsies in the era of high-tech medicine: discrepant findings persist. Journal of Clinical Pathology, 2014, 67, 512-519.	2.0	77
29	Whole slide images for primary diagnostics of gastrointestinal tract pathology: a feasibility study. Human Pathology, 2012, 43, 702-707.	2.0	76
30	High frequency of HIF-1Î± overexpression in BRCA1 related breast cancer. Breast Cancer Research and Treatment, 2008, 111, 475-480.	2.5	74
31	The role of hypoxia inducible factor-1alpha in gynecological cancer. Critical Reviews in Oncology/Hematology, 2011, 78, 173-184.	4.4	73
32	First clinical experience with a dedicated MRI-guided high-intensity focused ultrasound system for breast cancer ablation. European Radiology, 2016, 26, 4037-4046.	4.5	72
33	Mitosis Counting in Breast Cancer: Object-Level Interobserver Agreement and Comparison to an Automatic Method. PLoS ONE, 2016, 11, e0161286.	2.5	72
34	Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. European Journal of Cancer, 2017, 82, 219-227.	2.8	71
35	Interlaboratory variability of Ki67 staining in breast cancer. European Journal of Cancer, 2017, 84, 219-227.	2.8	70
36	Evaluating the benefits of digital pathology implementation: time savings in laboratory logistics. Histopathology, 2018, 73, 784-794.	2.9	70

#	Article	IF	Citations
37	Whole slide images for primary diagnostics in dermatopathology: a feasibility study. Journal of Clinical Pathology, 2012, 65, 152-158.	2.0	69
38	Supplemental Breast MRI for Women with Extremely Dense Breasts: Results of the Second Screening Round of the DENSE Trial. Radiology, 2021, 299, 278-286.	7.3	66
39	Being fully digital: perspective of a Dutch academic pathology laboratory. Histopathology, 2019, 75, 621-635.	2.9	65
40	Tubal ligation and risk of ovarian cancer. Lancet, The, 2001, 358, 844.	13.7	64
41	Genetic analysis of 53 lymph node-negative breast carcinomas by CGH and relation to clinical, pathological, morphometric, and DNA cytometric prognostic factors. Journal of Pathology, 1998, 186, 356-362.	4.5	62
42	Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer. Modern Pathology, 2016, 29, 1460-1470.	5.5	62
43	Comparison of the prognostic value of four methods to assess mitotic activity in 186 invasive breast cancer patients: Classical and random mitotic activity assessments with correction for volume percentage of epithelium. Human Pathology, 1995, 26, 1086-1092.	2.0	60
44	Digital slide images for primary diagnostics in breast pathology: a feasibility study. Human Pathology, 2012, 43, 2318-2325.	2.0	58
45	FER kinase promotes breast cancer metastasis by regulating Î±6- and Î²1-integrin-dependent cell adhesion and anoikis resistance. Oncogene, 2013, 32, 5582-5592.	5.9	58
46	Targeting mitochondrial translation by inhibiting DDX3: a novel radiosensitization strategy for cancer treatment. Oncogene, 2018, 37, 63-74.	5.9	58
47	Targeting RNA helicases in cancer: The translation trap. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 510-520.	7.4	57
48	Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases. Cancer Research, 2018, 78, 3112-3121.	0.9	57
49	BRCA1 and BRCA2 germline mutation analysis in the Indonesian population. Breast Cancer Research and Treatment, 2007, 106, 297-304.	2.5	56
50	RK-33 Radiosensitizes Prostate Cancer Cells by Blocking the RNA Helicase DDX3. Cancer Research, 2016, 76, 6340-6350.	0.9	56
51	Whole slide images as a platform for initial diagnostics in histopathology in a medium-sized routine laboratory. Journal of Clinical Pathology, 2012, 65, 1107-1111.	2.0	55
52	E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer. Scientific Reports, 2018, 8, 15454.	3.3	55
53	p300 and p53 levels determine activation of HIF-1 downstream targets in invasive breast cancerâˆ†. Human Pathology, 2006, 37, 1085-1092.	2.0	54
54	Hypoxia-Targeting Fluorescent Nanobodies for Optical Molecular Imaging of Pre-Invasive Breast Cancer. Molecular Imaging and Biology, 2016, 18, 535-544.	2.6	54

#	Article	IF	Citations
55	Origins of ... image analysis in clinical pathology.. Journal of Clinical Pathology, 1997, 50, 365-370.	2.0	53
56	Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplification. Breast Cancer Research and Treatment, 2012, 135, 49-58.	2.5	53
57	The Multicenter Morphometric Mammary Carcinoma Project (MMMCP). Pathology Research and Practice, 1989, 185, 664-670.	2.3	51
58	Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session. Journal of Controlled Release, 2020, 323, 269-281.	9.9	49
59	Expression of the RNA Helicase DDX3 and the Hypoxia Response in Breast Cancer. PLoS ONE, 2013, 8, e63548.	2.5	49
60	Discordance in ERÎ±, PR and HER2 receptor status across different distant breast cancer metastases within the same patient. Annals of Oncology, 2013, 24, 3017-3023.	1.2	47
61	Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases. Clinical and Experimental Metastasis, 2019, 36, 29-37.	3.3	47
62	Spatial collagen stiffening promotes collective breast cancer cell invasion by reinforcing extracellular matrix alignment. Oncogene, 2022, 41, 2458-2469.	5.9	47
63	The invasive front in endometrial carcinoma: higher proliferation and associated derailment of cell cycle regulators. Human Pathology, 2007, 38, 1232-1238.	2.0	46
64	Evaluation of Mitotic Activity Index in Breast Cancer Using Whole Slide Digital Images. PLoS ONE, 2013, 8, e82576.	2.5	46
65	Relationships between vascularization and proliferation in invasive breast cancer. , 1999, 189, 309-318.		45
66	Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer. Journal of Clinical Oncology, 2016, 34, 2107-2114.	1.6	45
67	Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. Journal of Clinical Oncology, 2022, 40, 2361-2374.	1.6	45
68	Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer. Breast Cancer Research and Treatment, 2012, 136, 705-715.	2.5	44
69	Optical imaging of pre-invasive breast cancer with a combination of VHHs targeting CAIX and HER2 increases contrast and facilitates tumour characterization. EJNMMI Research, 2016, 6, 14.	2.5	43
70	USP6-Associated Neoplasms: A Rapidly Expanding Family of Lesions. International Journal of Surgical Pathology, 2020, 28, 816-825.	0.8	42
71	Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients: Identification rate and influence on axillary treatment. European Journal of Cancer, 2015, 51, 915-921.	2.8	41
72	Tumor-stroma ratio as prognostic factor for survival in rectal adenocarcinoma: A retrospective cohort study. World Journal of Gastrointestinal Oncology, 2017, 9, 466-474.	2.0	41

#	Article	IF	Citations
73	Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis. Cancers, 2021, 13, 5694.	3.7	41
74	Contemporary risks of local and regional recurrence and contralateral breast cancer in patients treated for primary breast cancer. European Journal of Cancer, 2016, 63, 118-126.	2.8	40
75	Fibro-osseous pseudotumor of digits - Expanding the spectrum of clonal transient neoplasms harboring USP6 rearrangement. Annals of Diagnostic Pathology, 2018, 35, 53-55.	1.3	38
76	Tumor Response After Neoadjuvant Magnetic Resonance Guided Single Ablative Dose Partial Breast Irradiation. International Journal of Radiation Oncology Biology Physics, 2020, 106, 821-829.	0.8	38
77	Significant interâ€•and intraâ€laboratory variation in grading of invasive breast cancer: A nationwide study of 33,043 patients in the Netherlands. International Journal of Cancer, 2020, 146, 769-780.	5.1	37
78	Counting mitoses by image processing in Feulgen stained breast cancer sections: The influence of resolution. Cytometry, 1997, 28, 135-140.	1.8	36
79	Prolonged Neoadjuvant Chemotherapy with GMâ€CSF in Locally Advanced Breast Cancer. Oncologist, 1999, 4, 106-111.	3.7	36
80	Amide chemical exchange saturation transfer at 7ÂT: a possible biomarker for detecting early response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Research, 2018, 20, 51.	5.0	36
81	Tablet, Web-Based, or Paper Questionnaires for Measuring Anxiety in Patients Suspected of Breast Cancer: Patients' Preferences and Quality of Collected Data. Journal of Medical Internet Research, 2014, 16, e239.	4.3	36
82	HER-2/neuTesting and Therapy in Gastroesophageal Adenocarcinoma. Pathology Research International, 2011, 2011, 1-10.	1.4	35
83	Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment: a study protocol. BMC Cancer, 2017, 17, 181.	2.6	35
84	Genomic evolution from primary breast carcinoma to distant metastasis: Few copy number changes of breast cancer related genes. Cancer Letters, 2014, 344, 138-146.	7.2	34
85	Cytokeratin and protein expression patterns in squamous cell carcinoma of the oral cavity provide evidence for two distinct pathogenetic pathways. Oncology Letters, 2016, 12, 107-113.	1.8	34
86	Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer. Cancer Research, 2017, 77, 623-631.	0.9	34
87	Î±Eâ€catenin is a candidate tumor suppressor for the development of Eâ€cadherinâ€expressing lobularâ€type breast cancer. Journal of Pathology, 2018, 245, 456-467.	4.5	34
88	Comprehensive trends in incidence, treatment, survival and mortality of first primary invasive breast cancer stratified by age, stage and receptor subtype in the Netherlands between 1989 and 2017. International Journal of Cancer, 2021, 148, 2289-2303.	5.1	34
89	Whole slide images for primary diagnostics of paediatric pathology specimens: a feasibility study. Journal of Clinical Pathology, 2013, 66, 218-223.	2.0	33
90	St Gallen 2015 subtyping of luminal breast cancers: impact of different Ki67-based proliferation assessment methods. Breast Cancer Research and Treatment, 2016, 159, 257-263.	2.5	33

#	Article	IF	Citations
91	Rapid on-site evaluation during endoscopic ultrasoundguided fine-needle aspiration of lymph nodes does not increase diagnostic yield: A randomized, multicenter trial. American Journal of Gastroenterology, 2018, 113, 677-685.	0.4	33
92	Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases. BMC Cancer, 2014, 14, 864.	2.6	32
93	Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Modern Pathology, 2017, 30, 509-518.	5.5	32
94	Acute cellular and vascular responses to photodynamic therapy using EGFR-targeted nanobody-photosensitizer conjugates studied with intravital optical imaging and magnetic resonance imaging. Theranostics, 2020, 10, 2436-2452.	10.0	32
95	Discrimination between benign and malignant prostate tissue using chromatin texture analysis in 3â€Ð by confocal laser scanning microscopy. Prostate, 2007, 67, 248-254.	2.3	31
96	Immunophenotyping of male breast cancer. Histopathology, 2012, 61, 1145-1155.	2.9	31
97	Targeting DDX3 in Medulloblastoma Using the Small Molecule Inhibitor RK-33. Translational Oncology, 2019, 12, 96-105.	3.7	31
98	Grading of invasive breast carcinoma: the way forward. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 33-43.	2.8	31
99	Progressive APOBEC3B mRNA expression in distant breast cancer metastases. PLoS ONE, 2017, 12, e0171343.	2.5	31
100	Prediction of positive resection margins in patients with non-palpable breast cancer. European Journal of Surgical Oncology, 2015, 41, 106-112.	1.0	30
101	Sequencing of DICER1 in sarcomas identifies biallelic somatic DICER1 mutations in an adult-onset embryonal rhabdomyosarcoma. British Journal of Cancer, 2017, 116, 1621-1626.	6.4	30
102	A Novel Diagnostic Tool for Selecting Patients With Mesenchymal-Type Colon Cancer Reveals Intratumor Subtype Heterogeneity. Journal of the National Cancer Institute, 2017, 109, .	6.3	30
103	Significant inter- and intra-laboratory variation in grading of ductal carcinoma in situ of the breast: a nationwide study of 4901 patients in the Netherlands. Breast Cancer Research and Treatment, 2019, 174, 479-488.	2.5	30
104	Relevant impact of central pathology review on nodal classification in individual breast cancer patients. Annals of Oncology, 2012, 23, 2561-2566.	1.2	29
105	Artificial intelligence applied to breast pathology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 191-209.	2.8	29
106	The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent. European Journal of Cancer, 2007, 43, 527-535.	2.8	28
107	Fibroblast growth factor receptor 3 protein is overexpressed in oral and oropharyngeal squamous cell carcinoma. Cancer Medicine, 2016, 5, 275-284.	2.8	28
108	The prognostic effect of DDX3 upregulation in distant breast cancer metastases. Clinical and Experimental Metastasis, 2017, 34, 85-92.	3.3	28

#	Article	IF	Citations
109	Sex matters: men with melanoma have a worse prognosis than women. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2062-2067.	2.4	28
110	Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas. Journal of Clinical Oncology, 2021, 39, 1243-1252.	1.6	28
111	Meta-analysis of the concordance of histological grade of breast cancer between core needle biopsy and surgical excision specimen. British Journal of Surgery, 2016, 103, 644-655.	0.3	27
112	Systematic review and meta-analysis of the diagnostic accuracy of ductoscopy in patients with pathological nipple discharge. British Journal of Surgery, 2016, 103, 632-643.	0.3	27
113	The molecular genetic make-up of male breast cancer. Endocrine-Related Cancer, 2019, 26, 779-794.	3.1	27
114	Molecular Analysis of Nipple Fluid for Breast Cancer Screening. Pathobiology, 2008, 75, 149-152.	3.8	26
115	Cathepsin K associates with lymph node metastasis and poor prognosis in oral squamous cell carcinoma. BMC Cancer, 2018, 18, 385.	2.6	26
116	Hypoxiaâ€inducible factor 1Î± is essential for hypoxic p27 induction in endometrioid endometrial carcinoma. Journal of Pathology, 2008, 214, 38-45.	4.5	25
117	Fluorescent stains for quantification of DNA by confocal laser scanning microscopy in 3-D. Biotechnic and Histochemistry, 2008, 83, 63-69.	1.3	25
118	Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer. Cellular Oncology (Dordrecht), 2011, 34, 3-10.	4.4	25
119	Bone metastasis treatment using magnetic resonance-guided high intensity focused ultrasound. Bone, 2015, 81, 513-523.	2.9	25
120	Trends in Sentinel Lymph Node Biopsy Enactment for Cutaneous Melanoma. Annals of Surgical Oncology, 2019, 26, 1494-1502.	1.5	25
121	Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. Annals of Oncology, 2021, 32, 375-383.	1.2	25
122	Promoter hypermethylation using 24-gene array in early head and neck cancer. Epigenetics, 2014, 9, 1220-1227.	2.7	24
123	Radiofrequency ablation of small breast tumours: Evaluation of a novel bipolar cool-tip application. European Journal of Surgical Oncology, 2014, 40, 1222-1229.	1.0	24
124	The reliability of histological grade in breast cancer core needle biopsies depends on biopsy size: a comparative study with subsequent surgical excisions. Histopathology, 2016, 69, 1047-1054.	2.9	24
125	Fibroblast Growth Factor Receptor Family Members as Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review. Targeted Oncology, 2016, 11, 17-27.	3.6	24
126	Whole slide images for primary diagnostics of urinary system pathology: a feasibility study. Journal of Renal Injury Prevention, 2014, 3, 91-6.	0.2	24

#	Article	IF	Citations
127	Unravelling site-specific breast cancer metastasis: a microRNA expression profiling study. Oncotarget, 2017, 8, 3111-3123.	1.8	24
128	DNA promoter hypermethylation in nipple fluid: a potential tool for early breast cancer detection. Oncotarget, 2016, 7, 24778-24791.	1.8	24
129	SlideToolkit: An Assistive Toolset for the Histological Quantification of Whole Slide Images. PLoS ONE, 2014, 9, e110289.	2.5	23
130	Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer. Medical Oncology, 2017, 34, 33.	2.5	23
131	Digital pathology in the time of corona. Journal of Clinical Pathology, 2020, 73, 706-712.	2.0	23
132	Successful oxytocin-assisted nipple aspiration in women at increased risk for breast cancer. Familial Cancer, 2010, 9, 321-325.	1.9	22
133	Immunophenotyping invasive breast cancer: paving the road for molecular imaging. BMC Cancer, 2012, 12, 240.	2.6	22
134	The Effects of Under 6 Hours of Formalin Fixation on Hormone Receptor and HER2 Expression in Invasive Breast Cancer. American Journal of Clinical Pathology, 2014, 142, 16-22.	0.7	22
135	Nuclear DDX3 expression predicts poor outcome in colorectal and breast cancer. OncoTargets and Therapy, 2017, Volume 10, 3501-3513.	2.0	22
136	Methylation-Specific Multiplex Ligation-Dependent Probe Amplification (MS-MLPA). Methods in Molecular Biology, 2018, 1708, 537-549.	0.9	22
137	Ethical considerations for modern molecular pathology. Journal of Pathology, 2018, 246, 405-414.	4.5	22
138	Prognostic modeling of oral cancer by gene profiles and clinicopathological co-variables. Oncotarget, 2017, 8, 59312-59323.	1.8	22
139	Molecular Differences between Ductal CarcinomaIn Situand Adjacent Invasive Breast Carcinoma: A Multiplex Ligation-Dependent Probe Amplification Study. Analytical Cellular Pathology, 2010, 33, 165-173.	1.4	21
140	CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. Breast Cancer Research and Treatment, 2013, 139, 649-655.	2.5	21
141	Intratumoral heterogeneity of Ki67 expression in early breast cancers exceeds variability between individual tumours. Histopathology, 2016, 69, 849-861.	2.9	21
142	Global Effects of DDX3 Inhibition on Cell Cycle Regulation Identified by a Combined Phosphoproteomics and Single Cell Tracking Approach. Translational Oncology, 2018, 11, 755-763.	3.7	21
143	Pregnancy-associated breast cancer: nationwide Dutch study confirms a discriminatory aggressive histopathologic profile. Breast Cancer Research and Treatment, 2021, 186, 699-704.	2.5	21
144	Association of Histologic Regression With a Favorable Outcome in Patients With Stage 1 and Stage 2 Cutaneous Melanoma. JAMA Dermatology, 2021, 157, 166.	4.1	21

#	Article	IF	Citations
145	Comparison of multiplex ligation dependent probe amplification to immunohistochemistry for assessing HER-2/neuamplification in invasive breast cancer. Biotechnic and Histochemistry, 2006, 81, 79-85.	1.3	20
146	The Microanatomic Location of Metastatic Breast Cancer in Sentinel Lymph Nodes Predicts Nonsentinel Lymph Node Involvement. Annals of Surgical Oncology, 2008, 15, 1309-1315.	1.5	20
147	Subcellular FIH-1 expression patterns in invasive breast cancer in relation to HIF-1Î± expression. Cellular Oncology (Dordrecht), 2011, 34, 565-570.	4.4	20
148	Clonal intratumor heterogeneity of promoter hypermethylation in breast cancer by MS-MLPA. Modern Pathology, 2014, 27, 869-874.	5.5	20
149	Comparison of Survival Between Patients With Single vs Multiple Primary Cutaneous Melanomas. JAMA Dermatology, 2019, 155, 1049.	4.1	20
150	Early detection of changes in phospholipid metabolism during neoadjuvant chemotherapy in breast cancer patients using phosphorus magnetic resonance spectroscopy at 7T. NMR in Biomedicine, 2019, 32, e4086.	2.8	20
151	Deep learning-based grading of ductal carcinoma in situ in breast histopathology images. Laboratory Investigation, 2021, 101, 525-533.	3.7	20
152	miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers. Oncotarget, 2015, 6, 32115-32137.	1.8	20
153	Interventional ductoscopy in patients with pathological nipple discharge. British Journal of Surgery, 2015, 102, 1639-1648.	0.3	19
154	Moral Duties of Genomics Researchers: Why Personalized Medicine Requires a Collective Approach. Trends in Genetics, 2017, 33, 118-128.	6.7	19
155	Revisiting the impact of age and molecular subtype on overall survival after radiotherapy in breast cancer patients. Scientific Reports, 2017, 7, 12587.	3.3	19
156	Site-specific gene expression patterns in oral cancer. Head & Face Medicine, 2017, 13, 6.	2.1	19
157	Rocky road to digital diagnostics: implementation issues and exhilarating experiences. Journal of Clinical Pathology, 2021, 74, 415-420.	2.0	19
158	Phase I feasibility study of Magnetic Resonance guided High Intensity Focused Ultrasound-induced hyperthermia, Lyso-Thermosensitive Liposomal Doxorubicin and cyclophosphamide in de novo stage IV breast cancer patients: study protocol of the i-GO study. BMJ Open, 2020, 10, e040162.	1.9	19
159	Interâ€observer agreement for the histological diagnosis of invasive lobular breast carcinoma. Journal of Pathology: Clinical Research, 2022, 8, 191-205.	3.0	19
160	Oxytocin: bringing magic into nipple aspiration. Annals of Oncology, 2007, 18, 1743-1744.	1.2	18
161	Hypoxia-Inducible Factor-1 as a Therapeutic Target in Endometrial Cancer Management. Obstetrics and Gynecology International, 2010, 2010, 1-8.	1.3	18
162	Differential Expression of Growth Factor Receptors and Membrane-Bound Tumor Markers for Imaging in Male and Female Breast Cancer. PLoS ONE, 2013, 8, e53353.	2.5	18

#	Article	IF	Citations
163	Clinical significance and molecular annotation of cellular morphometric subtypes in lower-grade gliomas discovered by machine learning. Neuro-Oncology, 2023, 25, 68-81.	1.2	18
164	Progression risk of columnar cell lesions of the breast diagnosed in core needle biopsies. International Journal of Cancer, 2011, 129, 2674-2680.	5.1	17
165	Same-Day Diagnosis Based on Histology for Women Suspected of Breast Cancer: High Diagnostic Accuracy and Favorable Impact on the Patient. PLoS ONE, 2014, 9, e103105.	2.5	17
166	p120-catenin prevents multinucleation through control of MKLP1-dependent RhoA activity during cytokinesis. Nature Communications, 2016, 7, 13874.	12.8	17
167	FGFR Family Members Protein Expression as Prognostic Markers in Oral Cavity and Oropharyngeal Squamous Cell Carcinoma. Molecular Diagnosis and Therapy, 2016, 20, 363-374.	3.8	17
168	Validation of a wholeâ€slide imageâ€based teleconsultation network. Histopathology, 2018, 73, 777-783.	2.9	17
169	ESR1 Amplification is Rare in Breast Cancer and is Associated with High Grade and High Proliferation: A Multiplex Ligation-Dependent Probe Amplification Study. Analytical Cellular Pathology, 2010, 33, 13-18.	1.4	16
170	Sentinel lymph node localization with contrast-enhanced ultrasound and an I-125 seed: An ideal prospective development study. International Journal of Surgery, 2015, 14, 1-6.	2.7	16
171	Tracing differences between male and female breast cancer: both diseases own a different biology. Histopathology, 2015, 67, 888-897.	2.9	16
172	DDX3 has divergent roles in head and neck squamous cell carcinomas in smokingversusnon-smoking patients. Oral Diseases, 2015, 21, 270-271.	3.0	16
173	Mutational analysis using Sanger and next generation sequencing in sporadic spindle cell hemangiomas: A study of 19 cases. Genes Chromosomes and Cancer, 2017, 56, 855-860.	2.8	16
174	Inflammatory breast cancer: The pathologists' perspective. European Journal of Surgical Oncology, 2018, 44, 1128-1134.	1.0	16
175	Pathology Image Exchange: The Dutch Digital Pathology Platform for Exchange of Whole-Slide Images for Efficient Teleconsultation, Telerevision, and Virtual Expert Panels. JCO Clinical Cancer Informatics, 2019, 3, 1-7.	2.1	16
176	Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study. Breast Cancer Research and Treatment, 2020, 183, 759-770.	2.5	16
177	Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands. Breast Cancer Research and Treatment, 2019, 175, 487-497.	2.5	15
178	ESR1 Amplification in Breast Cancer by Optimized RNase FISH: Frequent but Low-Level and Heterogeneous. PLoS ONE, 2013, 8, e84189.	2.5	14
179	Effects of magnetic resonance-guided high-intensity focused ultrasound ablation on bone mechanical properties and modeling. Journal of Therapeutic Ultrasound, 2015, 3, 13.	2.2	14
180	Interlaboratory Variability in the Histologic Grading of Colorectal Adenocarcinomas in a Nationwide Cohort. American Journal of Surgical Pathology, 2016, 40, 1100-1108.	3.7	14

#	Article	IF	Citations
181	Interlaboratory variability in the grading of dysplasia in a nationwide cohort of colorectal adenomas. Histopathology, 2016, 69, 187-197.	2.9	14
182	Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy. Oncotarget, 2017, 8, 55550-55561.	1.8	14
183	The theranostic target prostate-specific membrane antigen is expressed in medullary thyroid cancer. Human Pathology, 2018, 81, 245-254.	2.0	14
184	Increased Levels of Oxidative Damage in Liver Metastases Compared with Corresponding Primary Colorectal Tumors. American Journal of Pathology, 2018, 188, 2369-2377.	3.8	14
185	Predicting sentinel node positivity in patients with melanoma: external validation of a riskâ€prediction calculator (the Melanoma Institute Australia nomogram) using a large European populationâ€based patient cohort*. British Journal of Dermatology, 2021, 185, 412-418.	1.5	14
186	Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer. Oncotarget, 2016, 7, 63537-63548.	1.8	14
187	Copy number changes at 8p11-12 predict adverse clinical outcome and chemo- and radiotherapy response in breast cancer. Oncotarget, 2018, 9, 17078-17092.	1.8	14
188	Prospective multicenter comparison of proliferation and other prognostic factors in lymph node negative lobular invasive breast cancer. Breast Cancer Research and Treatment, 2010, 121, 35-40.	2.5	13
189	Analysis of gene copy number alterations by multiplex ligation-dependent probe amplification in columnar cell lesions of the breast. Cellular Oncology (Dordrecht), 2014, 37, 147-154.	4.4	13
190	Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study. European Journal of Cancer, 2018, 90, 92-101.	2.8	13
191	Desmoplastic melanoma: The role of pure and mixed subtype in sentinel lymph node biopsy and survival. Cancer Medicine, 2020, 9, 671-677.	2.8	13
192	Expression of the stem cell marker ALDH1 in the normal breast of BRCA1 mutation carriers. Breast Cancer Research and Treatment, 2010, 123, 611-612.	2.5	12
193	HIF-1Î± and NOTCH signaling in ductal and lobular carcinomas of the breast. Cellular Oncology (Dordrecht), 2012, 35, 435-442.	4.4	12
194	Chromosome 17 copy number changes in male breast cancer. Cellular Oncology (Dordrecht), 2015, 38, 237-245.	4.4	12
195	The Pisotriquetral Joint: Osteoarthritis and Enthesopathy. Journal of Hand and Microsurgery, 2016, 06, 18-25.	0.3	12
196	High Prevalence of MRI-Detected Contralateral and Ipsilateral Malignant Findings in Patients With Invasive Ductolobular Breast Cancer: Impact on Surgical Management. Clinical Breast Cancer, 2016, 16, 269-275.	2.4	12
197	Significant Inter- and Intralaboratory Variation in Gleason Grading of Prostate Cancer: A Nationwide Study of 35,258 Patients in The Netherlands. Cancers, 2021, 13, 5378.	3.7	12
198	Chromosome 16q loss--a genetic key to the understanding of breast carcinogenesis. Histology and Histopathology, 2013, 28, 311-20.	0.7	12

#	Article	IF	Citations
199	ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer. Journal of Cancer, 2015, 6, 1079-1086.	2.5	11
200	Repeated Nipple Fluid Aspiration: Compliance and Feasibility Results from a Prospective Multicenter Study. PLoS ONE, 2015, 10, e0127895.	2.5	11
201	Promoter hypermethylation profiling of distant breast cancer metastases. Breast Cancer Research and Treatment, 2015, 151, 41-55.	2.5	11
202	Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markers. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 473-481.	2.8	11
203	Reliability of the Ki67-Labelling Index in Core Needle Biopsies of Luminal Breast Cancers is Unaffected by Biopsy Volume. Annals of Surgical Oncology, 2017, 24, 1251-1257.	1.5	11
204	Long-term prognosis of young breast cancer patients (â‰¤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study. BMJ Open, 2017, 7, e017842.	1.9	11
205	Ex vivo feasibility study of endoscopic intraductal laser ablation of the breast. Lasers in Surgery and Medicine, 2018, 50, 137-142.	2.1	11
206	Network Meta-analysis for the Diagnostic Approach to Pathologic Nipple Discharge. Clinical Breast Cancer, 2020, 20, e723-e748.	2.4	11
207	Tumor-Infiltrating Lymphocytes in Low-Risk Patients With Breast Cancer Treated With Single-Dose Preoperative Partial Breast Irradiation. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1325-1331.	0.8	11
208	Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice. Oncotarget, 2017, 8, 60750-60763.	1.8	11
209	Pathology Issues Related to SN Procedures and Increased Detection of Micrometastases and Isolated Tumor Cells. Breast Disease, 2010, 31, 65-81.	0.8	10
210	Expression of Connective Tissue Growth Factor in Male Breast Cancer: Clinicopathologic Correlations and Prognostic Value. PLoS ONE, 2015, 10, e0118957.	2.5	10
211	Methylation biomarkers for pleomorphic lobular breast cancer - a short report. Cellular Oncology (Dordrecht), 2015, 38, 397-405.	4.4	10
212	Copy number profiling by array comparative genomic hybridization identifies frequently occurring <scp>BRCA</scp>2â€like male breast cancer. Genes Chromosomes and Cancer, 2015, 54, 734-744.	2.8	10
213	Improved quality of patient care through routine second review of histopathology specimens prior to multidisciplinary meetings. Journal of Clinical Pathology, 2016, 69, 866-871.	2.0	10
214	PD-1 and PD-L1 Expression in Male Breast Cancer in Comparison with Female Breast Cancer. Targeted Oncology, 2018, 13, 769-777.	3.6	10
215	Role of columnar cell lesions in breast carcinogenesis: analysis of chromosome 16 copy number changes by multiplex ligation-dependent probe amplification. Modern Pathology, 2018, 31, 1816-1833.	5.5	10
216	Clinical versus histological grading in the assessment of cutaneous graft versus host disease. European Journal of Medical Research, 2019, 24, 19.	2.2	10

#	Article	IF	Citations
217	Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in earlyâ€stage luminal breast cancer. Histopathology, 2020, 77, 579-587.	2.9	10
218	The effect of an e-learning module on grading variation of (pre)malignant breast lesions. Modern Pathology, 2020, 33, 1961-1967.	5.5	10
219	Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (ax) Tj ETQq1 1 0.784314 rgBT /Ove sentinel lymph node (SN): Results from the MIRROR study. Journal of Clinical Oncology, 2009, 27, CRA506-CRA506.	1.6	10
220	Lessons Learned from Setting Up a Prospective, Longitudinal, Multicenter Study with Women at High Risk for Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 441-449.	2.5	10
221	Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer. Oncogene, 2022, 41, 2932-2944.	5.9	10
222	Implementation of Artificial Intelligence in Diagnostic Practice as a Next Step after Going Digital: The UMC Utrecht Perspective. Diagnostics, 2022, 12, 1042.	2.6	10
223	SSTR2A expression in medullary thyroid carcinoma is correlated with longer survival. Endocrine, 2018, 62, 639-647.	2.3	9
224	Stereotactic 9-gauge vacuum-assisted breast biopsy, how many specimens are needed?. European Journal of Radiology, 2019, 120, 108665.	2.6	9
225	Variation in breast cancer grading: the effect of creating awareness through laboratory-specific and pathologist-specific feedback reports in 16 734 patients with breast cancer. Journal of Clinical Pathology, 2020, 73, 793-799.	2.0	9
226	Reducing False-Positive Screening MRI Rate in Women with Extremely Dense Breasts Using Prediction Models Based on Data from the DENSE Trial. Radiology, 2021, 301, 283-292.	7.3	9
227	Role of DDX3 in the pathogenesis of inflammatory bowel disease. Oncotarget, 2017, 8, 115280-115289.	1.8	9
228	Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (ax) Tj ETQq0 0 0 rgBT /Overlock 10 Tf sentinel lymph node (SN): Results from the MIRROR study. Journal of Clinical Oncology, 2009, 27, CRA506-CRA506.	1.6	9
229	Discrepancy between routine and expert pathologists' assessment of non-palpable breast cancer and its impact on locoregional and systemic treatment. European Journal of Pharmacology, 2013, 717, 31-35.	3.5	8
230	Prognostic Value of Mitotic Index and Bcl2 Expression in Male Breast Cancer. PLoS ONE, 2013, 8, e60138.	2.5	8
231	Do columnar cell lesions exist in the male breast?. Histopathology, 2014, 64, 818-825.	2.9	8
232	Impact of preoperative evaluation of tumour grade by core needle biopsy on clinical risk assessment and patient selection for adjuvant systemic treatment in breast cancer. British Journal of Surgery, 2015, 102, 1048-1055.	0.3	8
233	Methylation Profile of X-Chromosomeâ€“Related Genes in Male Breast Cancer. Frontiers in Oncology, 2020, 10, 784.	2.8	8
234	Detection of breast cancer precursor lesions by autofluorescence ductoscopy. Breast Cancer, 2021, 28, 119-129.	2.9	8

#	Article	IF	Citations
235	Prospects of Targeting the Gastrin Releasing Peptide Receptor and Somatostatin Receptor 2 for Nuclear Imaging and Therapy in Metastatic Breast Cancer. PLoS ONE, 2017, 12, e0170536.	2.5	8
236	Promoter hypermethylation in ductal carcinoma in situ of the male breast. Endocrine-Related Cancer, 2019, 26, 575-584.	3.1	8
237	The effects of magnetic resonance imaging-guided high-intensity focused ultrasound ablation on human cadaver breast tissue. European Journal of Pharmacology, 2013, 717, 21-30.	3.5	7
238	Correlation between E-cadherin and p120 expression in invasive ductal breast cancer with a lobular component and MRI findings. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 707-712.	2.8	7
239	Performance of 4 Immunohistochemical Phosphohistone H3 Antibodies for Marking Mitotic Figures in Breast Cancer. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 20-26.	1.2	7
240	Intraâ€nodal nevi in sentinel nodeâ€negative patients with cutaneous melanoma does not influence survival. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2291-2295.	2.4	7
241	The Changing Role of Gene-Expression Profiling in the Era of De-escalating Adjuvant Chemotherapy in Early-Stage Breast Cancer. Annals of Surgical Oncology, 2019, 26, 3495-3501.	1.5	7
242	Luminal A versus luminal B breast cancer: MammaTyper mRNA versus immunohistochemical subtyping with an emphasis on standardised Ki67 labellingâ€based or mitotic activity indexâ€based proliferation assessment. Histopathology, 2020, 76, 650-660.	2.9	7
243	Segmentation and Classification of Melanoma and Nevus in Whole Slide Images. , 2020, , .		7
244	Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data. British Journal of Surgery, 2021, 108, 550-553.	0.3	7
245	Socioeconomic status significantly contributes to the likelihood of immediate postmastectomy breast reconstruction in the Netherlands: A nationwide study. European Journal of Surgical Oncology, 2021, 47, 245-250.	1.0	7
246	Meta-analysis and cost-effectiveness of ductoscopy, duct excision surgery and MRI for the diagnosis and treatment of patients with pathological nipple discharge. Breast Cancer Research and Treatment, 2021, 186, 285-293.	2.5	7
247	Intraoperative MET-receptor targeted fluorescent imaging and spectroscopy for lymph node detection in papillary thyroid cancer: novel diagnostic tools for more selective central lymph node compartment dissection. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3557-3570.	6.4	7
248	Nipple Aspirate Fluid at a Glance. Cancers, 2022, 14, 159.	3.7	7
249	Low Levels ofBNIP3Promoter Hypermethylation in Invasive Breast Cancer. Analytical Cellular Pathology, 2010, 33, 175-176.	1.4	6
250	Epigenetic biomarkers in the diagnosis of ovarian cancer. Expert Opinion on Medical Diagnostics, 2012, 6, 421-438.	1.6	6
251	Analysis of expression of membrane-bound tumor markers in ductal carcinoma in situ of the breast: paving the way for molecular imaging. Cellular Oncology (Dordrecht), 2013, 36, 333-340.	4.4	6
252	Brief fixation does not hamper the reliability of Ki67 analysis in breast cancer coreâ€needle biopsies: a doubleâ€centre study. Histopathology, 2015, 66, 380-387.	2.9	6

#	Article	IF	Citations
253	Predicting turnaround time reductions of the diagnostic track in the histopathology laboratory using mathematical modelling. Journal of Clinical Pathology, 2016, 69, 793-800.	2.0	6
254	Copy number profiling of oncogenes in ductal carcinoma in situ of the male breast. Endocrine-Related Cancer, 2018, 25, 173-184.	3.1	6
255	Application of Nipple Aspirate Fluid miRNA Profiles for Early Breast Cancer Detection and Management. International Journal of Molecular Sciences, 2019, 20, 5814.	4.1	6
256	Grading variation in 2,934 patients with ductal carcinoma in situ of the breast: the effect of laboratory- and pathologist-specific feedback reports. Diagnostic Pathology, 2020, 15, 52.	2.0	6
257	Cytoplasmic DDX3 as prognosticator in male breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 647-655.	2.8	6
258	Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients. Journal of the National Cancer Institute, 2021, 113, 1506-1514.	6.3	6
259	Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (ax) Tj ETQq1 1 0.784314 rgBT /Overlo sentinel lymph node (SN): Results from the MIRROR study. Journal of Clinical Oncology, 2009, 27, CRA506-CRA506.	1.6	6
260	Lack of association between CDKN2A germline mutations and survival in patients with melanoma: A retrospective cohort study. Journal of the American Academy of Dermatology, 2022, 87, 479-482.	1.2	6
261	Prognosis of pregnancy-associated breast cancer: inferior outcome in patients diagnosed during second and third gestational trimesters and lactation. Breast Cancer Research and Treatment, 2022, 192, 175-189.	2.5	6
262	Signal transduction pathway activity in high-grade serous carcinoma, its precursors and Fallopian tube epithelium. Gynecologic Oncology, 2022, 165, 114-120.	1.4	6
263	Cadaveric tissue donation: a pathologist's perspective. Journal of Medical Ethics, 2003, 29, 135-136.	1.8	5
264	St. Gallen endocrine response classes predict recurrence rates over time. Breast, 2015, 24, 705-712.	2.2	5
265	Hypoxia-inducible factor 1-Î± in chronic gastrointestinal ischemia. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 125-132.	2.8	5
266	Histopathology of breast cancer after magnetic resonanceâ€guided highâ€intensity focused ultrasound and radiofrequency ablation. Histopathology, 2016, 69, 250-259.	2.9	5
267	Assessment of <scp>HER</scp>2 status in breast cancer biopsies is not affected by accelerated tissue processing. Histopathology, 2018, 73, 81-89.	2.9	5
268	Batch scheduling in the histopathology laboratory. Flexible Services and Manufacturing Journal, 2018, 30, 171-197.	3.4	5
269	Quantifying the Mitigating Effects of Whole-Breast Radiotherapy and Systemic Treatments on Regional Recurrence Incidence Among Breast Cancer Patients. Annals of Surgical Oncology, 2020, 27, 3402-3411.	1.5	5
270	Receptor status of breast cancer diagnosed during pregnancy: A literature review. Critical Reviews in Oncology/Hematology, 2021, 168, 103494.	4.4	5

#	Article	IF	Citations
271	OUP accepted manuscript. Clinical Chemistry, 2022, , .	3.2	5
272	Corrections to â€œBreast cancer histopathology image analysis: A reviewâ€•[May 14 1400-1411]. IEEE Transactions on Biomedical Engineering, 2014, 61, 2819-2819.	4.2	4
273	Validity of whole slide images for scoring HER2 chromogenic in situ hybridisation in breast cancer. Journal of Clinical Pathology, 2016, 69, 992-997.	2.0	4
274	Prognostic models in male breast cancer. Breast Cancer Research and Treatment, 2016, 160, 339-346.	2.5	4
275	Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study. Genes, 2018, 9, 261.	2.4	4
276	Thick melanomas without lymph node metastases: A forgotten group with poor prognosis. European Journal of Surgical Oncology, 2020, 46, 918-923.	1.0	4
277	The Physiological MicroRNA Landscape in Nipple Aspirate Fluid: Differences and Similarities with Breast Tissue, Breast Milk, Plasma and Serum. International Journal of Molecular Sciences, 2020, 21, 8466.	4.1	4
278	Expression of hypoxia-induced proteins in ductal carcinoma in situ and invasive cancer of the male breast. Journal of Clinical Pathology, 2020, 73, 204-208.	2.0	4
279	Breast Cancer and Major Deviations of Genetic and Gender-related Structures and Function. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3065-e3074.	3.6	4
280	The increasing importance of histologic grading in tailoring adjuvant systemic therapy in 30,843 breast cancer patients. Breast Cancer Research and Treatment, 2021, 187, 577-586.	2.5	4
281	Blunt duct adenosis: a separate entity from columnar cell lesions?. Journal of Clinical Pathology, 2022, 75, 5-9.	2.0	4
282	High discordance rate in assessing sentinel node positivity in cutaneous melanoma: Expert review may reduce unjustified adjuvant treatment. European Journal of Cancer, 2021, 149, 105-113.	2.8	4
283	Validation of digital microscopy: Review of validation methods and sources of bias. Veterinary Pathology, 2022, 59, 26-38.	1.7	4
284	The changing microRNA landscape by color and cloudiness: a cautionary tale for nipple aspirate fluid biomarker analysis. Cellular Oncology (Dordrecht), 2021, 44, 1339-1349.	4.4	4
285	Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes. European Journal of Cancer, 2022, 167, 123-132.	2.8	4
286	A restaining method to restore faded fluorescence in tissue specimens for quantitative confocal microscopy. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2007, 71A, 875-881.	1.5	3
287	Comprehensive Proteomic Profilingâ€“derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas. American Journal of Surgical Pathology, 2018, 42, 1262-1272.	3.7	3
288	Patient-reported outcomes of ductoscopy procedures for pathologic nipple discharge. Breast Cancer, 2021, 28, 471-477.	2.9	3

#	Article	IF	Citations
289	Heterogeneity in signaling pathway activity within primary breast cancer and between primary and metastases.. Journal of Clinical Oncology, 2019, 37, 589-589.	1.6	3
290	Dynamic Contrast-enhanced and Diffusion-weighted Magnetic Resonance Imaging for Response Evaluation After Single-Dose Ablative Neoadjuvant Partial Breast Irradiation. Advances in Radiation Oncology, 2022, 7, 100854.	1.2	3
291	The progressive relationship between increasing Breslow thickness and decreasing survival is lost in patients with ultrathick melanomas (â‰¥15Âmm in thickness). Journal of the American Academy of Dermatology, 2022, 87, 298-305.	1.2	3
292	Value of routine cytokeratin immunohistochemistry in detecting low volume disease in cervical cancer. Gynecologic Oncology, 2022, 165, 257-263.	1.4	3
293	Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients. European Journal of Cancer, 2022, 167, 133-141.	2.8	3
294	The diagnostic process of cervical cancer; areas of good practice, and windows of opportunity. Gynecologic Oncology, 2015, 138, 405-410.	1.4	2
295	Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant. Modern Pathology, 2017, 30, 15-25.	5.5	2
296	Probability of sentinel lymph node positivity in melanoma. European Journal of Cancer, 2019, 116, 10-12.	2.8	2
297	Elastosis in ERÎ±-positive male breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 257-263.	2.8	2
298	Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer. Breast Cancer Research and Treatment, 2021, 185, 817-830.	2.5	2
299	Heterogeneity in Signaling Pathway Activity within Primary and between Primary and Metastatic Breast Cancer. Cancers, 2021, 13, 1345.	3.7	2
300	Can automatic image analysis replace the pathologist in cardiac allograft rejection diagnosis?. European Heart Journal, 2021, 42, 2370-2372.	2.2	2
301	Patientsâ€™ perceptions of 70-gene signature testing: commonly changing the initial inclination to undergo or forego chemotherapy and reducing decisional conflict. Breast Cancer Research and Treatment, 2020, 182, 107-115.	2.5	2
302	Conditional Inactivation of HIF-1 Using Intrabodies. Analytical Cellular Pathology, 2008, 30, 397-409.	1.4	2
303	HER-2/neu Amplification Testing in Breast Cancer by Multiplex Ligation-Dependent Probe Amplification in Comparison with Immunohistochemistry and In Situ Hybridization. Analytical Cellular Pathology, 2009, 31, 1-10.	1.4	2
304	Optimal endocrine therapy for breast cancer patients 45-50 years of age at diagnosis.. Journal of Clinical Oncology, 2016, 34, 551-551.	1.6	2
305	Cyclic activity of signal transduction pathways in fimbrial epithelium of the human fallopian tube. Acta Obstetricia Et Gynecologica Scandinavica, 2022, 101, 256-264.	2.8	2
306	Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature. Breast Cancer Research and Treatment, 2022, , .	2.5	2

#	Article	IF	Citations
307	Interlaboratory Gleason grading variation affects treatment: a Dutch historic cohort study in 30 509 patients with prostate cancer. Journal of Clinical Pathology, 2023, 76, 690-697.	2.0	2
308	Cost-effectiveness of adjuvant systemic therapy in low-risk breast cancer patients with nodal isolated tumor cells or micrometastases. Annals of Oncology, 2012, 23, 2585-2591.	1.2	1
309	Genetic analysis of 53 lymph node-negative breast carcinomas by CGH and relation to clinical, pathological, morphometric, and DNA cytometric prognostic factors. , 1998, 186, 356.		1
310	Genomic Profiling by Array Comparative Genomic Hybridization Reveals Novel DNA Copy Number Changes in Breast Phyllodes Tumours. Analytical Cellular Pathology, 2009, 31, 31-39.	1.4	1
311	Validation of a Fully Automated HER2 Staining Kit in Breast Cancer. Analytical Cellular Pathology, 2010, 32, 149-155.	1.4	1
312	Multiplex Ligation-Dependent Probe Amplification to Detect HER2 Amplification in Breast Cancer: New Insights in Optimal Cut-Off Value. Analytical Cellular Pathology, 2010, 32, 311-312.	1.4	1
313	Superficial basal cell carcinoma, think deeper: Step sectioning of skin biopsy specimens yields 14% more aggressive subtypes. PLoS ONE, 2022, 17, e0256149.	2.5	1
314	Re: Tissue Banks Trigger Worry About Ownership Issues. Journal of the National Cancer Institute, 2007, 99, 253-253.	6.3	0
315	Comparative immunohistochemical investigation of rat and human hepatocellular carcinomas. Journal of Histotechnology, 2013, 36, 75-85.	0.5	0
316	Response to A. Matikas et al.. Journal of the National Cancer Institute, 2018, 110, 1282-1283.	6.3	0
317	ASO Author Reflections: Sentinel Lymph Node Biopsy Trend in Melanoma: The More the Merrier. Annals of Surgical Oncology, 2019, 26, 723-724.	1.5	0
318	Re: The Association Between Hysterectomy and Ovarian Cancer Risk: A Population-Based Record-Linkage Study. Journal of the National Cancer Institute, 2019, 111, 1361-1361.	6.3	0
319	Unique Case of a Rare Mesenchymal Tumor Harboring a Somatic c.119delC VHL Mutation. JCO Precision Oncology, 2019, 3, 1-8.	3.0	0
320	In Reply to Tsoutsou. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1251-1252.	0.8	0
321	Confocal 3D DNA Cytometry: Assessment of Required Coefficient of Variation by Computer Simulation. Analytical Cellular Pathology, 2006, 28, 123-123.	1.4	0
322	Association of the phosphorylation of the estrogen receptor at serine 118 and 167 with prognosis in postmenopausal breast cancer patients.. Journal of Clinical Oncology, 2012, 30, 562-562.	1.6	0
323	Prophylaxis of hereditary breast cancer. Aging, 2017, 9, 2453-2454.	3.1	0
324	Patient-centered research: how do women tolerate nipple fluid aspiration as a potential screening tool for breast cancer?. BMC Cancer, 2022, 22, .	2.6	0